The Rocky Road to Useful Cancer Biomarkers
Authors: Jennifer Fisher Wilson
Journal: Annals of Internal Medicine (2006)

Current Clinical Issues20 June 2006The Rocky Road to Useful Cancer BiomarkersJennifer Fisher WilsonJennifer Fisher WilsonAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-144-12-200606200-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Biomarkers may be the future of cancer care, allowing earlier diagnosis and more efficient and effective treatment. Certainly, expectations for biomarkers are high, a result of the mapping of the human genome and the development of fast gene and protein analysis technology, as well as promising research reports. But the potential of biomarkers has been harder to realize than expected. Close examination has disproved some promising new biomarkers—specific molecules in the body, such as genes and proteins, that indicate disease—and other biomarkers have ultimately held limited clinical value. Mistakes have also occurred in some biomarker tests used to determine who ...References1. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009. [PMID: 12490681] CrossrefMedlineGoogle Scholar2. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005;365:488-92. [PMID: 15705458] CrossrefMedlineGoogle Scholar3. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-7. [PMID: 11867112] CrossrefMedlineGoogle Scholar4. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst. 2005;97:307-9. [PMID: 15713966] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Disclosures: None disclosed.E-mail: [email protected]org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLectura crítica de artículos de pruebas diagnósticas I: ¿Son válidos los resultados del estudio?Systems Biology and Systems MedicineMonitoring enzymatic degradation of pericellular matrices through SERS stampingPredictors of Progression in Barrett's Esophagus: Current Knowledge and Future DirectionsSystems Biology and Systems MedicineMolecular DiagnosticsSystems Biology and the Emergence of Systems MedicineTechnology Insight: biomarker development in acute kidney injury—what can we anticipate?Targeted diagnostics and therapeutics for individualized patient managementBiomarker Development, Commercialization, and Regulation: Individualization of Medicine Lost in TranslationBreast and Prostate Biopsies: Use of Optimized High-Throughput MicroRNA Expression for Diagnosis (Methodology) 20 June 2006Volume 144, Issue 12Page: 945-948KeywordsBreast cancerCancer treatmentClinical trialsDrugsFluorescence in situ hybridizationFood and Drug AdministrationOvarian cancerPatientsProteinsResearch laboratories ePublished: 20 June 2006 Issue Published: 20 June 2006 Copyright & PermissionsCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...